About Breath Therapeutics
Breath Therapeutics is a Healthcare company based in Munchen (Germany) founded in 2016, and was acquired by Zambon Pharma in July 2019. Inhalation therapies are developed for severe respiratory orphan diseases. Breath Therapeutics has raised $46.01 million across 1 funding round from investors including Gimv, Zambon Pharma and Gilde Healthcare. Breath Therapeutics offers products and services including Liposomal Cyclosporine A, Active Pharmaceutical Ingredients, and Zcube Solutions. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is Zambon Company S.P.A.
Company details
Breath Therapeutics, a spin-off of PARI Pharma, is developing inhalation therapies for delivering drugs for treating severe respiratory orphan diseases. The company is using proprietary drug formulations optimized for inhaled administration with exclusively licensed, high-performance nebulizers. Its lead product is a drug-device innovation for inhalation therapy to treat Bronchiolitis Obliterans Syndrome (BOS) in patients after lung transplantation. The companys inhalation therapy involves a formulation of liposomal cyclosporine A for inhalation and an optimized eFlow technology nebulizer enabling remote adherence monitoring. The company has completed phase 2 trials preparing to initiate two robust Phase 3 clinical trials in the US and Europe.
- Headquarters Munchen, Germany
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website breath-therapeutics.com
- Social LinkedIn X YouTube
- Acquired by Zambon Pharma (Jul 2019)
- Legal Name Zambon Company S.P.A.
- Total Equity Funding$46.01M (USD)
in 1 rounds
- Latest Funding Round$46.01M (USD), Series A
Mar 2017
- InvestorsGimv
& 3 more
- Acquired byZambon Pharma
(Jul 2019)
Products & Services of Breath Therapeutics
Breath Therapeutics offers a comprehensive portfolio of products and services, including Liposomal Cyclosporine A, Active Pharmaceutical Ingredients, and Zcube Solutions.
Inhalation therapy for Bronchiolitis Obliterans Syndrome patients
Develops intermediates for pharmaceutical industry applications
Identifies digital therapies to improve patient care outcomes
Apps and channels of Breath Therapeutics
its YouTube channel Zambon has 70 subscribers and 30 videos.
Videos from Breath Therapeutics
The most watched videos on Breath Therapeutics's YouTube channel, Zambon (70 subscribers). Click a video to play it here.
More on Zambon.
Funding Insights of Breath Therapeutics
Breath Therapeutics has successfully raised a total of $46.01M through 1 strategic funding round. The most recent funding activity was a Series A round of $46.01 million completed in March 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $46.01M
- Total Rounds 1
- Last Round Series A — $46.01M
- First Round $46.01M
(Mar 2017)
- Investors Count 3
All 1 funding rounds of Breath Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2017 | $46.01M | Series A | – | Gimv, Sofinnova Partners |
4 investors in total: 4 institutional.
Investors in Breath Therapeutics
Breath Therapeutics has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Gimv, Zambon Pharma and Gilde Healthcare.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm | 1980 | gimv.com | Antwerp, Belgium | |
Private equity and venture captial firm focused on healthcare sectors | gildehealthcare.com | Cambridge, United States | ||
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
APIs and finished drugs are developed and manufactured in pharmaceuticals. | 1906 | zambon.com | Bresso, Italy |
Investor details for Breath Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Breath Therapeutics
3 dated milestones of Breath Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Breath Therapeutics is founded.
- Funding First funding round of $46.0M.
- Exit Acquired by Zambon Pharma.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Breath Therapeutics
Complete news archive for Breath Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Breath Therapeutics
Breath Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Breath Therapeutics is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
Breath Therapeutics is a funded company, having raised a total of $46.01M across 1 funding round to date. The company's 1st funding round was a Series A of $46.01M, raised on Mar 2017.
Breath Therapeutics, a spin-off of PARI Pharma, is developing inhalation therapies for delivering drugs for treating severe respiratory orphan diseases. The company is using proprietary drug formulations optimized for inhaled administration with exclusively licensed, high-performance nebulizers. Its lead product is a drug-device innovation for inhalation therapy to treat Bronchiolitis Obliterans Syndrome (BOS) in patients after lung transplantation. The companys inhalation therapy involves a formulation of liposomal cyclosporine A for inhalation and an optimized eFlow technology nebulizer enabling remote adherence monitoring. The company has completed phase 2 trials preparing to initiate two robust Phase 3 clinical trials in the US and Europe.
Breath Therapeutics offers Liposomal Cyclosporine A, Active Pharmaceutical Ingredients, and Zcube Solutions.
Breath Therapeutics has 4 investors. Key investors include Gimv, Zambon Pharma, Gilde Healthcare, and Sofinnova Partners.
Breath Therapeutics operates through Zambon Company S.P.A..
Yes. Breath Therapeutics was acquired by Zambon Pharma in July 2019.